InPractice:

Clinical Insights

  • Detection of NPS in Buprenorphine Samples

    Detection of NPS in Buprenorphine Samples

    Aegis recently conducted a retrospective analysis of patient samples from individuals who were prescribed buprenorphine to ascertain how frequently novel…

  • Medication Monitoring in Behavioral Health

    Medication Monitoring in Behavioral Health

    Mental illness is common in the United States, with an estimated 52.9 million people – about 1 in 5 adults – experiencing mental illness.1 Of those 52.9…

  • BioDetect: Identifying Non-Urine Substances

    BioDetect: Identifying Non-Urine Substances

    Healthcare providers rely on medication adherence test results to assist in measuring compliance and evaluating recent substance use. Providers must remain…

  • An Overview of Testing Capabilities to Identify Use of Marijuana (THC) and Other Natural Cannabinoids

    An Overview of Testing Capabilities to Identify Use of Marijuana (THC) and Other Natural Cannabinoids

    Following the passing of the 2018 Agriculture Improvement Act (a.k.a. Farm Bill), the cannabis industry has seen widespread growth in products that contain…

  • Synthetic Stimulants

    Synthetic Stimulants

    Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs; however, they…

  • Nitazene Analogs

    Nitazene Analogs

    Nitazene analogs are a subclass of designer opioids that are structurally different from opioids but attach to the same mu-opioid receptor.1 This Novel…

  • Designer Benzodiazepines

    Designer Benzodiazepines

    Designer benzodiazepines (DZBDs) represent a major public health issue and their prevalence has increased substantially over the last decade.1 Slight alterations…